FindTrial
Sign In

Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514238-19-00
Acronym
VHIO17002
Enrollment
167
Registered
2024-10-01
Start date
2018-03-28
Completion date
Unknown
Last updated
2025-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects with advanced solid tumour

Brief summary

Module 1, 2 & 3: • Overall response rate (ORR) or complete response (CR) by RECIST 1.1 of different targeted agents in molecularly selected small patient populations. Specific to Module 1: * For patients with prostate cancer in arm 1G: ORR at 12 weeks ofatezolizumab by a composite of biochemical and/or objective radiographic responses according to Prostate Cancer Working Group 3 (PCWG3) and RECIST 1.1. No specific primary endpoint in iProfiler (Part A) protocol.

Interventions

DRUGFutibatinib
DRUGTecentriq 1 200 mg concentrate for solution for infusion
DRUGJNJ-61186372

Sponsors

Vall D Hebron Institute Of Oncology
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Module 1, 2 & 3: • Overall response rate (ORR) or complete response (CR) by RECIST 1.1 of different targeted agents in molecularly selected small patient populations. Specific to Module 1: * For patients with prostate cancer in arm 1G: ORR at 12 weeks ofatezolizumab by a composite of biochemical and/or objective radiographic responses according to Prostate Cancer Working Group 3 (PCWG3) and RECIST 1.1. No specific primary endpoint in iProfiler (Part A) protocol.—

Countries

France, Germany, Italy, Netherlands, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026